Healthcare Business

Vical $2 Million NIH Grant For Herpes Vaccine (VICL)

Vical, Incorporated (NASDAQ: VICL) has been awarded a $2 million Phase II small business technology transfer grant from the US National Institute of Allergy and Infectious Diseases department from the National Institues of Health.

The grant is to fund an ongoing development of Vical’s plasmid DNA vaccine against Herpes simplex virus type 2.  This is none other than the sexually transmitted virus that causes genital herpes.

Research is being conducted at the University of Wasington and the University of Texas. The goal of the study is to be used in people who already have HSV-2 with a primary goal of reducing or eliminating periodic herpes viral flare-ups and the associated viral shedding and transmission.

The potential list of users could be tens of millions and there is currently no such vaccine or drug that is a true cure for this.

Vical’s market cap is a mere $146 million.

Jon C. Ogg
April 3, 2008

Sponsored: Find a Qualified Financial Advisor

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.